Akebia Therapeutics Receivables

Akebia Therapeutics (AKBA) currently reports a receivables of $63M as of March 2026. That compares with $62M in the prior-year period — up 1.6% year over year. Use the charts on this page to explore Akebia Therapeutics's receivables history and peer comparisons.

Akebia Therapeutics's receivables increased from $62M to $63M — a 1.6% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Akebia Therapeutics reported $63M in receivables as of March 2026. That compares with $62M in the prior-year period — up 1.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $63M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Akebia Therapeutics, and consider following AKBA for alerts when major investors trade the stock.

Akebia Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $63M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AKBA with unrelated industries.